{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:27:09Z","timestamp":1783560429940,"version":"3.55.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":746,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.ijid.2011.03.017","type":"journal-article","created":{"date-parts":[[2011,5,23]],"date-time":"2011-05-23T01:08:03Z","timestamp":1306112883000},"page":"e438-e448","source":"Crossref","is-referenced-by-count":40,"title":["Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection"],"prefix":"10.1016","volume":"15","author":[{"given":"Caitlin R.","family":"Musgrave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Brandon","family":"Bookstaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Scott","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2011.03.017_bib0005","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1053\/j.gastro.2008.12.070","article-title":"Treatment of Clostridium difficile-associated disease","volume":"136","author":"Leffler","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijid.2011.03.017_bib0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.anaerobe.2009.09.004","article-title":"Clostridium difficile infection: historic review","volume":"15","author":"Bartlett","year":"2009","journal-title":"Anaerobe"},{"key":"10.1016\/j.ijid.2011.03.017_bib0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhin.2009.10.016","article-title":"Economic healthcare costs of Clostridium difficile infection: a systematic review","volume":"74","author":"Ghantoji","year":"2010","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.ijid.2011.03.017_bib0020","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3201\/eid1406.071447","article-title":"Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000\u20132005","volume":"14","author":"Zilberberg","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0025","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0030","unstructured":"Miller BA, Chen LF, Sexton DJ, Anderson DJ. The impact of hospital-onset healthcare facility associated (HO-HCFA) Clostridium difficile infection (CDI) in community hospitals: surpassing methicillin-resistant Staphylococcus aureus (MRSA) as the new superbug. Abstract presented at the Fifth Decennial International Conference on Healthcare-Associated Infections. March 18\u201322, 2010; Atlanta, Georgia, USA."},{"issue":"Suppl 1","key":"10.1016\/j.ijid.2011.03.017_bib0035","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0924-8579(09)70012-3","article-title":"New trends in Clostridium difficile virulence and pathogenesis","volume":"33","author":"Den\u00e8ve","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2011.03.017_bib0520","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1086\/596703","article-title":"Healt care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study","volume":"48","author":"Gravel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0045","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jana.2008.04.007","article-title":"Clostridium difficile-associated disease in the HIV-infected patient","volume":"19","author":"Makarewicz","year":"2008","journal-title":"J Assoc Nurses AIDS Care"},{"key":"10.1016\/j.ijid.2011.03.017_bib0050","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10096-006-0220-1","article-title":"Risk factors for Clostridium difficile-associated diarrhea on an adult hematology\u2013oncology ward","volume":"25","author":"Gifford","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0055","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/j.1469-0691.2009.03099.x","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI)","volume":"15","author":"Bauer","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.ijid.2011.03.017_bib0060","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004610.pub3","article-title":"Antibiotic treatment for Clostridium difficile-associated diarrhea in adults","author":"Nelson","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijid.2011.03.017_bib0065","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1086\/342334","article-title":"Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature","volume":"35","author":"Apisarnthanarak","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0070","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1128\/JCM.38.6.2386-2388.2000","article-title":"Epidemiology of recurrences or reinfections of Clostridium difficile associated diarrhea","volume":"38","author":"Barbut","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0195-6701(98)90062-7","article-title":"Recurrence of symptoms in Clostridium difficile infection\u2014relapse or reinfection?","volume":"38","author":"Wilcox","year":"1998","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.ijid.2011.03.017_bib0080","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1099\/jmm.0.45753-0","article-title":"Alternative treatments for Clostridium difficile disease: what really works?","volume":"54","author":"McFarland","year":"2005","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0085","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease","volume":"97","author":"McFarland","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0090","first-page":"867","article-title":"Approach to patients with multiple relapses of antimicrobial-associated pseudomembranous colitis","volume":"80","author":"Tedesco","year":"1985","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0095","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2146\/ajhp070077","article-title":"Current and future treatment modalities for Clostridium difficile-associated disease","volume":"65","author":"Halsey","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ijid.2011.03.017_bib0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1473-3099(09)70059-3","article-title":"The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea","volume":"9","author":"Parkes","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0105","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.anaerobe.2009.09.002","article-title":"Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections","volume":"15","author":"McFarland","year":"2009","journal-title":"Anaerobe"},{"key":"10.1016\/j.ijid.2011.03.017_bib0110","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/j.ijid.2009.01.014","article-title":"Bacteremia due to Clostridium difficile\u2014review of the literature","volume":"13","author":"Libby","year":"2009","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1472-765X.2006.01843.x","article-title":"Determination of survival, identity and stress resistance of probiotic bifidobacteria in bio-yoghurts","volume":"42","author":"Jayamanne","year":"2006","journal-title":"Lett Appl Microbiol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0120","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3201\/eid1611.100574","article-title":"Regulatory oversight and safety of probiotic use","volume":"16","author":"Venugopalan","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0125","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1572-0241.2006.00465.x","article-title":"Meta-analysis of probiotics for prevention of antibiotic associated diarrhea and treatment of Clostridium difficile disease","volume":"101","author":"McFarland","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/bmj.39231.599815.55","article-title":"Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial","volume":"335","author":"Hickson","year":"2007","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ijid.2011.03.017_bib0135","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004611.pub2","article-title":"Probiotics for treatment of Clostridium difficile-associated colitis in adults","author":"Pillai","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijid.2011.03.017_bib0140","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1099\/jmm.0.47697-0","article-title":"Designer probiotics: a potential therapeutic for Clostridium difficile?","volume":"57","author":"Sleator","year":"2008","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0145","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrmicro1349","article-title":"Designer probiotics for prevention of enteric infections","volume":"4","author":"Paton","year":"2006","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0150","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MCG.0b013e3181c87e02","article-title":"Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea","volume":"44","author":"Khoruts","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0155","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1086\/367657","article-title":"Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube","volume":"36","author":"Aas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.anaerobe.2009.09.007","article-title":"Fecal bacteriotherapy for recurrent Clostridium difficile infection","volume":"15","author":"Bakken","year":"2009","journal-title":"Anaerobe"},{"key":"10.1016\/j.ijid.2011.03.017_bib0165","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/01.mcg.0000128988.13808.dc","article-title":"Bacteriotherapy using fecal flora: toying with human motions","volume":"38","author":"Borody","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0170","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/MCG.0b013e3181dac035","article-title":"Treatment of refractory\/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients","volume":"44","author":"Yoon","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0175","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1086\/345676","article-title":"Colonization for the prevention of Clostridium difficile disease in hamsters","volume":"186","author":"Sambol","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF02097191","article-title":"Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain","volume":"6","author":"Seal","year":"1987","journal-title":"Eur J Clin Microbiol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0185","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1056\/NEJM200002103420604","article-title":"Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A","volume":"342","author":"Kyne","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2011.03.017_bib0190","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.vetmic.2007.04.019","article-title":"Prevention of porcine Clostridium difficile-associated disease by competitive exclusion with nontoxigenic organisms","volume":"124","author":"Songer","year":"2007","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0195","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/QCO.0b013e32833229ce","article-title":"Clostridium difficile: controversies and approaches to management","volume":"22","author":"Bauer","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0200","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00004836-199604000-00007","article-title":"Whole-bowel irrigation as an adjunct to the treatment of chronic, relapsing Clostridium difficile colitis","volume":"22","author":"Liacouras","year":"1996","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0205","first-page":"708","article-title":"The efficacy of polyethylene glycol-electrolyte lavage solution versus traditional mechanical bowel preparation for elective colonic surgery: a randomized, prospective, blinded clinical trial","volume":"98","author":"Fleites","year":"1985","journal-title":"Surgery"},{"key":"10.1016\/j.ijid.2011.03.017_bib0210","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijantimicag.2008.07.011","article-title":"Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer","volume":"33","author":"Weiss","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2011.03.017_bib0215","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0022-3476(76)81008-6","article-title":"Cholestyramine treatment of pseudomembranous colitis","volume":"88","author":"Sinatra","year":"1976","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijid.2011.03.017_bib0220","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/infdis\/141.1.92","article-title":"Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins","volume":"141","author":"Taylor","year":"1980","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0225","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/bjs.1800690306","article-title":"Randomized controlled trial of colestipol in antibiotic associated colitis","volume":"69","author":"Mogg","year":"1982","journal-title":"Br J Surg"},{"key":"10.1016\/j.ijid.2011.03.017_bib0230","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000199299","article-title":"Recurrent Clostridium difficile associated colitis responding to cholestyramine","volume":"33","author":"Kunimoto","year":"1986","journal-title":"Digestion"},{"key":"10.1016\/j.ijid.2011.03.017_bib0235","first-page":"175","article-title":"Multiple relapses of Clostridium difficile associated diarrhea responding to an extended course of cholestyramine","volume":"8","author":"Pruksananonda","year":"1989","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijid.2011.03.017_bib0240","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00043426-199211000-00015","article-title":"Multiple relapses of Clostridium difficile associated diarrhea in a cancer patient: successful control with long-term cholestyramine therapy","volume":"14","author":"Moncino","year":"1992","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0245","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ijantimicag.2007.06.006","article-title":"Lack of a physicochemical interaction between metronidazole and cholestyramine","volume":"30","author":"Wall","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2011.03.017_bib0250","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.3109\/03639048709116231","article-title":"Effect of concomitant oral administration of some adsorbing drugs on the bioavailability of metronidazole","volume":"13","author":"Molokhia","year":"1987","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.ijid.2011.03.017_bib0255","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/j.1365-2036.2006.03157.x","article-title":"Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties","volume":"24","author":"Barker","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ijid.2011.03.017_bib0260","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2125.2008.03151.x","article-title":"A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial","volume":"66","author":"Peppe","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0265","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1128\/AAC.01085-08","article-title":"Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection","volume":"53","author":"Baines","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2011.03.017_bib0270","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1086\/379153","article-title":"Oral administration of beta-lactamase preserves colonization resistance of piperacillin-treated mice","volume":"188","author":"Stiefel","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0275","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/jac\/dkn298","article-title":"Orally administered beta-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile","volume":"62","author":"Stiefel","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2011.03.017_bib0280","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/gut.41.3.366","article-title":"Intravenous immunoglobulin therapy for severe Clostridium difficile colitis","volume":"41","author":"Salcedo","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.ijid.2011.03.017_bib0285","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0022-3476(05)83393-1","article-title":"Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin","volume":"118","author":"Leung","year":"1991","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijid.2011.03.017_bib0525","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ijid.2008.11.012","article-title":"The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review","volume":"13","author":"O\u2019Horo","year":"2009","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0295","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/jhm.542","article-title":"Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature","volume":"5","author":"Abougergi","year":"2010","journal-title":"J Hosp Med"},{"key":"10.1016\/j.ijid.2011.03.017_bib0300","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s10350-006-0511-8","article-title":"Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea","volume":"49","author":"McPherson","year":"2006","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ijid.2011.03.017_bib0305","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMoa0907635","article-title":"Treatment with monoclonal antibodies against Clostridium difficile toxins","volume":"362","author":"Lowy","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2011.03.017_bib0310","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.vaccine.2009.10.144","article-title":"Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)","volume":"28","author":"Leav","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2011.03.017_bib0315","doi-asserted-by":"crossref","unstructured":"Monoclonal antibodies targeting Clostridium difficile licensed to Merck. Nat Rev Drug Discov 2009;8:442.","DOI":"10.1038\/nrd2911"},{"key":"10.1016\/j.ijid.2011.03.017_bib0320","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2004.11.004","article-title":"Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea","volume":"128","author":"Sougioultzis","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijid.2011.03.017_bib0325","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1016\/j.vaccine.2009.03.058","article-title":"A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A","volume":"27","author":"Gardiner","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.ijid.2011.03.017_bib0330","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1093\/clinids\/12.Supplement_1.S9","article-title":"In vitro antibacterial activity of bismuth subsalicylate","volume":"12","author":"Cornick","year":"1990","journal-title":"Rev Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ijid.2011.03.017_bib0335","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/clinids\/12.Supplement_1.S21","article-title":"Effect of bismuth subsalicylate on fecal microflora","volume":"12","author":"Gorbach","year":"1990","journal-title":"Rev Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ijid.2011.03.017_bib0340","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/clinids\/12.Supplement_1.S57","article-title":"Effect of bismuth subsalicylate on Clostridium difficile colitis in hamsters","volume":"12","author":"Chang","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0345","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1128\/AAC.49.1.431-433.2005","article-title":"Interaction of bismuth subsalicylate with fruit juices, ascorbic acid, and thiol-containing substrates to produce soluble bismuth products active against Clostridium difficile","volume":"49","author":"Mahony","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2011.03.017_bib0350","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1345\/aph.1K675","article-title":"Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea","volume":"42","author":"Garey","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijid.2011.03.017_bib0355","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3748\/wjg.v10.i5.765","article-title":"Successful treatment with rifampin for fulminant antibiotic-associated colitis in a patient with non-Hodgkin's lymphoma","volume":"10","author":"Nomura","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0360","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00004836-198704000-00009","article-title":"Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin","volume":"9","author":"Buggy","year":"1987","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0365","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1086\/506354","article-title":"Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea","volume":"43","author":"Lagrotteria","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0370","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000007297","article-title":"In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species","volume":"46","author":"Marchese","year":"2000","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijid.2011.03.017_bib0375","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1086\/511870","article-title":"Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin","volume":"33","author":"Johnson","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0530","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MCG.0b013e31814a4e97","article-title":"Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study","volume":"43","author":"Garey","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0385","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/lt.22092","article-title":"Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: a case series","volume":"16","author":"Neff","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ijid.2011.03.017_bib0390","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1756283X10372985","article-title":"Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial","volume":"3","author":"Basu","year":"2010","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"10.1016\/j.ijid.2011.03.017_bib0395","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004932.pub2","article-title":"Prevention and treatment of cryptosporidiosis in immunocompromised patients","author":"Abubakar","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijid.2011.03.017_bib0400","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11908-009-0004-8","article-title":"New antimicrobial agents for patients with Clostridium difficile infections","volume":"11","author":"Bartlett","year":"2009","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.ijid.2011.03.017_bib0405","doi-asserted-by":"crossref","unstructured":"Freeman J, Baines SD, Todhunter SL, Huscroft GS, Wilcox MH. Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole. J Antimicrob Chemother 2011 Mar 9 [Epub ahead of print].","DOI":"10.1093\/jac\/dkr077"},{"key":"10.1016\/j.ijid.2011.03.017_bib0410","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1128\/AAC.44.9.2254-2258.2000","article-title":"In vitro and in vivo activities of nitazoxanide against Clostridium difficile","volume":"44","author":"McVay","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2011.03.017_bib0415","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1086\/506351","article-title":"Nitazoxanide for the treatment of Clostridium difficile colitis","volume":"43","author":"Musher","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0420","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1086\/596552","article-title":"Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study","volume":"48","author":"Musher","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0425","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/00365540903244543","article-title":"In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the Tigecycline Evaluation and Surveillance Trial (TEST)","volume":"42","author":"Nagy","year":"2010","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0430","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1086\/599224","article-title":"Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection","volume":"48","author":"Herpers","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0435","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijantimicag.2009.11.008","article-title":"Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole","volume":"35","author":"Lu","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2011.03.017_bib0440","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/0310057X1003800339","article-title":"Failure of tigecycline to treat severe Clostridium difficile infection","volume":"38","author":"Kopterides","year":"2010","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.ijid.2011.03.017_bib0445","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/j.1469-0691.2007.01792.x","article-title":"Evidence for low risk of Clostridium difficile infection associated with tigecycline","volume":"13","author":"Wilcox","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2011.03.017_bib0450","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1128\/AAC.46.5.1617-1618.2002","article-title":"In vitro activity of linezolid against Clostridium difficile","volume":"46","author":"Pel\u00e1ez","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2011.03.017_bib0455","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/jac\/dkg113","article-title":"In vitro activity of linezolid against Clostridium difficile","volume":"51","author":"Ackermann","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2011.03.017_bib0460","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/00365540110076714","article-title":"Ecological effects of linezolid versus amoxicillin\/clavulanic acid on the normal intestinal microflora","volume":"33","author":"Lode","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijid.2011.03.017_bib0465","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s15010-005-4112-6","article-title":"Linezolid contributed to Clostridium difficile colitis with fatal outcome","volume":"33","author":"Zabel","year":"2005","journal-title":"Infection"},{"key":"10.1016\/j.ijid.2011.03.017_bib0470","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1179\/joc.2003.15.3.299","article-title":"Failure of intravenous linezolid to treat Clostridium difficile associated diarrhea","volume":"15","author":"Lazzarini","year":"2003","journal-title":"J Chemother"},{"key":"10.1016\/j.ijid.2011.03.017_bib0475","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1128\/AAC.49.3.1157-1159.2005","article-title":"In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole","volume":"49","author":"Pel\u00e1ez","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2011.03.017_bib0480","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1586\/14787210.4.6.939","article-title":"Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent","volume":"4","author":"Fulco","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Pt 11","key":"10.1016\/j.ijid.2011.03.017_bib0485","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1099\/mic.0.042010-0","article-title":"A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin","volume":"156","author":"Tannock","year":"2010","journal-title":"Microbiology"},{"key":"10.1016\/j.ijid.2011.03.017_bib0490","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1345\/aph.1M351","article-title":"Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection","volume":"44","author":"Sullivan","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijid.2011.03.017_bib0495","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2217\/fmb.10.20","article-title":"Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections","volume":"5","author":"Poxton","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijid.2011.03.017_bib0500","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2011.03.017_bib0505","unstructured":"Crook D, Peto T, Miller MA, Louie T, Cornely O, Shue YK, Gorbach S. Efficacy and safety of fidaxomicin (FDX) vs vancomycin (VAN) in Clostridium difficile infection (CDI) in 2 randomized controlled trials (RCT) with 1105 patients. Abstract presented at the 48th Annual Meeting of the Infectious Diseases Society of America. October 21-24, 2010; Vancouver, Canada."},{"key":"10.1016\/j.ijid.2011.03.017_bib0510","unstructured":"Fidaxomicin fact sheet. San Diego, CA: Optimer Pharmaceuticals, Inc.; 2011. Available at: http:\/\/www.optimerpharma.com\/fidaxomicin-docs (accessed March 14, 2011)."},{"key":"10.1016\/j.ijid.2011.03.017_bib0515","unstructured":"Optimer Pharmaceuticals News and Press. Optimer Pharmaceuticals announces FDA acceptance of NDA for filing and designation of priority review for fidaxomicin for the treatment of Clostridium difficile infection (CDI). San Diego, CA: Optimer Pharmaceuticals, Inc.; 2011. Available at: http:\/\/www.optimerpharma.com\/news.asp?news_story=145&page_num=&year=2011 (accessed March 14, 2011)."}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971211000737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971211000737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T23:13:25Z","timestamp":1637709205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971211000737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":103,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S1201971211000737"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2011.03.017","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}